RAPT Therapeutics (RAPT) announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by RAPT. Leerink Partners, TD Cowen, Guggenheim Securities, Wells Fargo Securities and LifeSci Capital are acting as joint bookrunning managers for the proposed offering. H.C. Wainwright & Co. and Clear Street are acting as lead managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics price target raised to $48 from $38 at Wells Fargo
- Rapt Therapeutics price target raised to $60 from $41 at Clear Street
- RAPT Therapeutics Reports Positive Phase 2 Trial Results
- Rapt Therapeutics price target raised to $58 from $35 at Barclays
- RAPT Therapeutics’ Promising Phase 2 Results and Strategic Advancements Drive Buy Rating